Shares in Smith & Nephew slid 3.2% to £1,122 on August 7, extending a week-long selloff that has erased more than 6% since the medical-device maker disclosed on August 4 that its top line is growing far more slowly than promised. The company now expects full-year underlying revenue growth of around 4%, down from a prior forecast of roughly 6%, after Q2 growth of just 1.6% badly missed analysts' expectations of 3.7%. For shareholders, the question is whether profit discipline can substitute for the revenue momentum they were counting on.
U.S. Knees Are the Weak Link — and There's No Quick Fix
CEO Deepak Nath conceded the shortfall is largely "company-specific," centered on U.S. knee implants where Smith & Nephew cannot yet offer a cementless version — the fastest-growing segment of the knee market.
A cementless knee system is expected in Q3 2026 , but catching up in a market where rivals already have traction will take quarters, not weeks. Until that gap closes, orthopaedics — the company's largest division — drags on overall growth.
Wound Care Added a Second Headache
Advanced Wound Bioactives declined due to U.S. reimbursement changes for skin substitutes that hit volumes and pricing, plus a surprisingly soft quarter for the company's key enzymatic wound product.
The skin-substitute headwind is now expected to reach the upper end of the $20–$40 million full-year drag range. That is a modest dollar amount, but it undercuts the narrative that Smith & Nephew's wound-care portfolio provides reliable ballast.
Cost Cuts Are Plugging the Hole — For Now
Management is maintaining full-year targets for trading profit (~$1.3 billion), free cash flow (~$800 million), and return on invested capital (>10%).
It is doing so by squeezing an extra $50 million in efficiency savings, bringing the 2026 total to roughly $200 million.
First-half trading profit grew 8.1% to $566 million, with margins up 60 basis points to 18.3%. That is genuinely impressive, but investors are right to wonder how much more cost there is to cut if revenue remains sluggish.
Sports Medicine Is the Bright Spot — With a Caveat
Sports Medicine & ENT revenue grew 8.6% on an underlying basis.
Yet even this division faces headwinds, including volume-based government procurement in China in the second half, which will pressure pricing.
The stock's slide says investors aren't buying the "profit on track" story while the top line decelerates. Until the new knee system ships and U.S. orthopaedics stabilizes, the burden of proof remains squarely on management.